Increase text sizeDecrease text sizeDefault text size

Paper: Protecting investment in biologic medicines – biological medicines, biosimilars and the challenges they pose

15 September 2016

In Brief: This series of articles is directed towards the part of biotech that is ‘pharmaceutical’, rather than diagnostic or bioengineering technologies, and, in particular, towards biologic medicines.

These are medicines that have been made or modified using biological systems, ie living organisms or their derivatives.

>> Download a PDF copy of the paper.

For further information, please contact:

Share or Save for later

What are these?


To save this publication on your smartphone or
tablet for off-line reading (eg on a plane flight),
we recommend Pocket.